Loading
AVC-203 is an experimental allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy from AvenCell Therapeutics, in phase 1 trials for relapsed/refractory B-cell malignancies and diffuse large B-cell lymphoma.
AVC-203 (Allo-QuadCAR01-T) is an allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy from AvenCell Therapeutics, with AvenCell Europe GmbH as partner. Off-the-shelf donor CAR-T cells, CRISPR-engineered, that target cells expressing CD19 and/or CD20, built on the switchable RevCAR receptor so other targets can be added through bridging proteins. Its furthest stage is phase 1, for relapsed/refractory B-cell malignancies and diffuse large B-cell lymphoma. No clinical trial naming it is registered on ClinicalTrials.gov. First patient dosed in phase 1 QUADvance in April 2026 (company release 2 April 2026); registry phase 1/2 recruiting (NCT07284433). It has not been shown to work in people.
1.AVC-203 slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AVC-203" OR ABSTRACT:"AVC-203" OR TITLE:"Allo-QuadCAR01-T" OR ABSTRACT:"Allo-QuadCAR01-T") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AVC-203, not a curated reading list.
Shares AvenCell Therapeutics, CD20, CD19 and the tag pipeline.
Shares AvenCell Therapeutics and the tag pipeline.
Shares AvenCell Therapeutics and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares AvenCell Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/